Clinical biomarker profiling revealed divergent LCN2 dynamics in neurodegenerative cohorts: cerebrospinal fluid (CSF) LCN2 depletion concurrent with plasma elevation in mild cognitive impairment (MCI) and AD patients.9 Plasma LCN2 levels demonstrated inverse correlation with Clinical Dementia Rating (CDR) scores and positive association with Mini-Mental State Examination (MMSE) metrics, establishing its prognostic utility for tracking MCI-to-AD conversion trajectories. Here, LCN2 is linked to Alzheimer disease.